Stock Ratings / Health Care / BRVE / insiders

ADRX (52) TRAX (33) MLYS (43) ZBIO (39) ⌘ Pro Terminal →

Braveheart Bio Inc. (BRVE) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$21.19 -2.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Braveheart Bio Inc. (BRVE) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.91B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRVE)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BRVE Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BRVE)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BRVE. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRVE)

✓Walkthrough of BRVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BRVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.89%▼ DESCENDING CHANNEL

2026-10-30O $21.29H $21.77L $20.75C $21.19VOL 533.7K

RES: $26.82SUP: $14.04SMA50: $23.52SMA200: $24.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BRVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BRVE Butterfly Map → + Track BRVE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BRVE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BRVE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BRVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRVE)

Health Care Rank #405 of 1016 ⚔️ ADRX vs BRVE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BRVE vs. ADRX, TRAX, MLYS, ZBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Braveheart Bio Inc. (BRVE) ranks #405 by composite RQD confidence (47/100, grade D) and #271 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, BRVE leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. ADRX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with BRVE at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BRVE ACTIVE Braveheart Bio Inc.	D	47/100	—	—	—	-2.62%	$1.91B	Benchmark Subject
ADRX ADARx Pharmaceuticals Inc.	D+	52/100	—	—	—	-0.56%	$1.91B	/adrx-vs-brve →
TRAX First Tracks Biotherapeutics Inc.	E	33/100	—	—	-35.0%	-1.08%	$1.90B	/trax-vs-brve →
MLYS Mineralys Therapeutics Inc.	D-	43/100	—	—	-28.4%	-0.65%	$1.88B	/mlys-vs-brve →
ZBIO Zenas BioPharma Inc.	D-	39/100	—	—	-35.0%	-0.04%	$1.87B	/zbio-vs-brve →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002131524

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BRVE closed FY2025 with $89.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$89.3M	—

3. BRVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $21.19 (-2.62% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BRVE ranks #405 in composite RQD confidence.

How does BRVE compare to ADRX and TRAX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ADRX (ADARx Pharmaceuticals Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.91B) and TRAX (First Tracks Biotherapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BRVE?

Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BRVE trading relative to its 50-day, 200-day, and 52-week technical levels?

BRVE last traded at $21.19 (-2.62% on volume of 304,135 shares), positioning the stock -9.91% below its 50-day simple moving average ($23.52) and -12.55% below its 200-day simple moving average ($24.23). Across its 52-week range of $17.86 to $32.00, BRVE sits at the 23.6% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.54 to $23.84).

BRVE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BRVE insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BRVE leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: BRVE RQD Cockpit BRVE 12M Forecast BRVE Earnings & Move BRVE Dividends & DRIP BRVE Insiders & 13F BRVE Whale Options BRVE Profit Sankey BRVE News & Why